Scholar Rock Holding (SRRK) Capital Expenditures (QoQ) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 112.50% |
| Dec 31, 2025 | -61.90% |
| Sep 30, 2025 | -60.93% |
| Jun 30, 2025 | -20.66% |
| Mar 31, 2025 | 1,131.82% |
| Dec 31, 2024 | -29.03% |
| Sep 30, 2024 | -3.13% |
| Jun 30, 2024 | 146.15% |
| Jun 30, 2023 | 36.67% |
| Mar 31, 2023 | -96.85% |
| Dec 31, 2022 | 217.82% |
| Sep 30, 2022 | -259.37% |
| Jun 30, 2022 | 22.76% |
| Mar 31, 2022 | -23.80% |
| Dec 31, 2021 | -86.69% |
| Sep 30, 2021 | 342.75% |
| Jun 30, 2021 | -172.53% |
| Mar 31, 2021 | 17.12% |
| Dec 31, 2020 | 7.81% |
| Sep 30, 2020 | 570.70% |
| Jun 30, 2020 | 2,630.00% |
| Mar 31, 2020 | -99.32% |
| Dec 31, 2019 | -9.15% |
| Sep 30, 2019 | 454.82% |
| Jun 30, 2019 | -194.41% |
| Mar 31, 2019 | -31.10% |
| Dec 31, 2018 | 17.03% |
| Sep 30, 2018 | 234.64% |
| Jun 30, 2018 | 1,276.92% |
| Mar 31, 2018 | -95.70% |
| Dec 31, 2017 | 301.33% |